INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 177 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2020. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $97,000 | +19.8% | 3,775 | -65.0% | 0.03% | +28.6% |
| Q3 2019 | $81,000 | -60.1% | 10,800 | +20.0% | 0.02% | -44.7% |
| Q3 2018 | $203,000 | +21.6% | 9,000 | -4.3% | 0.04% | 0.0% |
| Q2 2018 | $167,000 | +943.8% | 9,400 | +754.5% | 0.04% | +850.0% |
| Q4 2017 | $16,000 | -91.7% | 1,100 | -90.7% | 0.00% | -81.8% |
| Q1 2017 | $192,000 | +47.7% | 11,830 | +37.6% | 0.02% | +37.5% |
| Q4 2016 | $130,000 | – | 8,600 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |